ScholarIQanswers from OpenAlex & ORCID
Olivier Chinot
ResearcherPublications, citations & collaboration network
Olivier Chinot is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Olivier Chinot have?
ScholarIQindexed works
Olivier Chinot has 594 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Olivier Chinot have?
ScholarIQcitation count
Olivier Chinot has 25,951 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Olivier Chinot?
ScholarIQh-index
Olivier Chinot has an h-index of 71 in OpenAlex.
What is the i10-index of Olivier Chinot?
ScholarIQi10-index
Olivier Chinot has an i10-index of 233 in OpenAlex.
What is the ORCID of Olivier Chinot?
ScholarIQorcid
The ORCID for Olivier Chinot is on the source record.
What is the OpenAlex record for Olivier Chinot?
ScholarIQopenalex
The OpenAlex for Olivier Chinot is on the source record.
What are the most-cited papers on Olivier Chinot?
ScholarIQmost cited works
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
Josep Garcia, Herbert I. Hurwitz, Alan B. Sandler, David Miles, Robert L. Coleman, Regula Deurloo, Olivier Chinot
Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire
on behalf of the EORTC QLG, Marieke van Leeuwen, Olga Husson, Paola Alberti, Juan Ignacio Arrarás, Olivier Chinot, Anna Costantini, Anne‐Sophie Darlington, Linda Dirven, Martin Eichler, Eva Hammerlid, Bernhard Holzner, Colin Johnson, Meropi Kontogianni, Trille Kristina Kjær, Ofir Morag, Sandra Nolte, Andrew Nordin, Andrea Pace, Monica Pinto, Katja Polz, John Ramage, Jaap C. Reijneveld, Samantha Serpentini, Krzysztof A. Tomaszewski, Vassilios Vassiliou, Irma M. Verdonck‐de Leeuw, Ingvild Vistad, Teresa Young, Neil K. Aaronson, Lonneke V. van de Poll‐Franse
Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network
Sophie Langner-Lemercier, Caroline Houillier, Carole Soussain, Hervé Ghesquières, Olivier Chinot, Luc Taillandier, Pierre Soubeyran, T. Lamy, Franck Morschhauser, Alexandra Benouaich‐Amiel, Guido Ahle, Marie‐Pierre Moles‐Moreau, Cécile Moluçon‐Chabrot, Pascal Bourquard, Ghandi Damaj, Fabrice Jardin, Delphine Larrieu, Emmanuel Gyan, Rémy Gressin, Arnaud Jaccard, Sylvain Choquet, Annie Brion, Olivier Casasnovas, Philippe Colin, Oumédaly Reman, Adrian Tempescul, Jean‐Pierre Marolleau, Michel Fabbro, Florian Naudet, Khê Hoang‐Xuan, Roch Houot
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
Martin J. van den Bent, Marica Eoli, Juan Manuel Sepúlveda-Sánchez, Marion Smits, Annemiek Walenkamp, Jean-Sebastian Frenel, Enrico Franceschi, Paul Clement, Olivier Chinot, Filip De Vos, Nicolas Whenham, Paul Sanghera, Michael Weller, H J Dubbink, Pim J. French, Jim Looman, Jyotirmoy Dey, Scott Krause, Pete Ansell, Sarah Nuyens, Maarten Spruyt, Joana Brilhante, Corneel Coens, Thierry Gorlia, Vassilis Golfinopoulos